| Literature DB >> 34834081 |
Hamid Saeed Shah1, Usman Nasrullah2, Sumera Zaib3, Faisal Usman4, Ajmal Khan5, Umar Farooq Gohar6, Jalal Uddin7, Imtiaz Khan8, Ahmed Al-Harrasi5.
Abstract
The rapidly growing global burden of cancer poses a major challenge to public health and demands a robust approach to access promising anticancer therapeutics. In parallel, nanotechnology approaches with various pharmacological properties offer efficacious clinical outcomes. The use of new artificial variants of nanosponges (NS) as a transporter of chemotherapeutic drugs to target cells has emerged as a very promising tool. Therefore, in this research, ethylcellulose (EC) NS were prepared using the ultrasonication assisted-emulsion solvent evaporation technique. Withaferin-A (WFA), an active ingredient in Withania somnifera, has been implanted into the nanospongic framework with enhanced anticancer properties. Inside the polymeric structure, WFA was efficiently entrapped (85 ± 11%). The drug (WFA) was found to be stable within polymeric nanosponges, as demonstrated by Fourier transform infrared (FTIR) spectroscopy and differential scanning calorimetry (DSC) studies. The WFA-NS had a diameter of 117 ± 4 nm and zeta potential of -39.02 ± 5.71 mV with a polydispersity index (PDI) of 0.419 ± 0.073. In addition, scanning electron microscopy (SEM) revealed the porous surface texture of WFA-NS. In vitro anticancer activity (SRB assay) results showed that WFA-NS exhibited almost twice the anticancer efficacy against MCF-7 cells (IC50 = 1.57 ± 0.091 µM), as quantified by flow cytometry and comet tests. Moreover, fluorescence microscopy with DAPI staining and analysis of DNA fragmentation revealed apoptosis as a mechanism of cancer cell death. The anticancer activity of WFA-NS was further determined in vivo and results were compared to cisplatin. The anticancer activity of WFA-NS was further investigated in vivo, and the data were consistent to those obtained with cisplatin. At Day 10, WFA-NS (10 mg/kg) significantly reduced tumour volume to 72 ± 6%, which was comparable to cisplatin (10 mg/kg), which reduced tumour volume to 78 ± 8%. Finally, the outcomes of molecular modeling (in silico) also suggested that WFA established a stable connection with nanosponges, generating persistent hydrophobic contacts (polar and nonpolar) and helping with the attractive delayed-release features of the formulation. Collectively, all the findings support the use of WFA in nanosponges as a prototype for cancer treatment, and opened up new avenues for increasing the efficacy of natural product-derived medications.Entities:
Keywords: DNA fragmentation; cancer therapeutics; cell cycle; drug release; flow cytometry; nanosponges; withaferin-A
Mesh:
Substances:
Year: 2021 PMID: 34834081 PMCID: PMC8623412 DOI: 10.3390/molecules26226990
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1The representation of DSC thermogram of WFA-NS, pure WFA, and free NS (A), and FTIR spectra of pure WFA, WFA-NS and free NS (B).
Figure 2Scanning electron microscopic analysis of WFA-NS (A), WFA release from NS (B), and hydrodynamic diameter of WFA-NS (C).
WFA-NS physical and kinetic characteristics (Mean ± S.D, n = 3).
| Analysis | Results |
|---|---|
| Diameter hydrodynamic | 117 ± 4 nm |
| Entrapment Efficiency (%) | 85 ± 11 |
| Zeta Potential (mV) | −39.02 ± 5.71 |
| Poly dispersity Index(PDI) | 0.389 ± 0.091 |
| Zero-order | 0.8734 |
| First-order | 0.9867 |
| Higuchi Model | 0.9806 |
| Korsemeyer Peppas, | 0.9713, 0.324 |
Figure 3The pharmacological characterization of WFA-NS, pure WFA, and free NS (IC50 data) (A), DAPI staining of untreated and treated MCF-7 cells (B,C).
Figure 4A representation of alkaline comet assay H2O2 (A), WFA-NS (B). DNA fragmentation analysis utilizing 1 Kb DNA ladder, pure WFA and WFA-NS (C). The flow cytometry analysis of untreated (D) pure WFA (E) and WFA-NS (F) against MCF-7 cells.
Figure 5Molecular details of nanosponges assembly (A,B). The single polyvinyl alcohol (yellow stick) molecule mediates hydrogen bonding with the ethylcellulose (magenta sticks) (A). The results of molecular modeling studies, the bottom panels showed the MS–MS surface view of nanosponges (C,D). In vivo anticancer studies conducted on mice (E) with 10 mg/kg of Cisplatin (●) 10 mg/kg of pure WFA (■), 2 mg/kg of WFA-NS (▲), 5 mg/kg of WFA-NS (▼), and 10 mg/kg of WFA-NS (♦). The WFA-NS formulation exhibited a substantially lower relative tumor volume than free WFA (p < 0.05).
The numerical data provides percent reduction in tumor volume after giving doses (mg/kg of a mouse).
| Percent Reduction in Tumor Volume | |||||
|---|---|---|---|---|---|
| Cisplatin (C) | WFA (D) | WFA-NS (E) | WFA-NS (F) | WFA-NS (G) | |
| DAY0 | 9 ± 3 | 6 ± 1 | 1 ± 1 | 3 ± 1 | 4 ± 1 |
| DAY2 | 12 ± 5 | 7 ± 2 | 5 ± 3 | 8 ± 2 | 14 ± 2 |
| DAY4 | 17 ± 3 | 13 ± 8 | 10 ± 6 | 12 ± 3 | 21 ± 7 |
| DAY6 | 41 ± 2 | 32 ± 11 | 16 ± 7 | 19 ± 6 | 45 ± 11 |
| DAY8 | 59 ± 10 | 48 ± 7 | 22 ± 11 | 35 ± 7 | 61 ± 8 |
| DAY10 | 78 ± 8 | 57 ± 12 | 31 ± 9 | 48 ± 11 | 72 ± 6 |
The anticancer effects of WFA, WFA-NS, and cisplatin were shown in both experimental and comparison groups of mice.
| Group | Type of Treatment |
|---|---|
| A | Water for injection in cancerous mice (WFI) |
| B | Free nanosponges (NS) for cancerous mice |
| C | Cancerous mice were given 10 mg/kg cisplatin |
| D | WFA (10 mg/kg) treated cancerous mice |
| E | WFA-NS (2 mg/kg) treated cancerous mice |
| F | WFA-NS (5 mg/kg) treated cancerous mice |
| G | WFA-NS (10 mg/kg) treated cancerous mice |